Blog
RSS FeedPosted by Michael Wonder on 17 May 2022
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults
17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...
Posted by Michael Wonder on 28 Apr 2022
Baqsimi (nasal glucagon), rescue treatment for severe hypoglycaemia now covered in British Colombia, Alberta & Saskatchewan
27 April 2022 - Lilly Canada is pleased to announce that as of 5 April 2022, Baqsimi (glucagon nasal powder) ...
Posted by Michael Wonder on 21 Apr 2022
Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...
Posted by Michael Wonder on 24 Feb 2022
AbbVie announces provincial reimbursement for Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia in Alberta, Saskatchewan, British Columbia and Manitoba
24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination ...
Posted by Michael Wonder on 21 Feb 2022
Drug funded for people with spinal muscular atrophy
15 February 2022 - The provincial government is covering costs for risdiplam, or Evrysdi, the medication used to treat a severe ...
Posted by Michael Wonder on 29 Mar 2021
B.C. woman petitions province to cover cost of 'life-changing' migraine medication
29 March 2021 - Christina Sall says Aimovig is the only drug that helps her, but it costs her more than ...
Posted by Michael Wonder on 10 Aug 2020
B.C. family nearing finish in race to raise $2.8 million to treat baby's rare disease
8 August 2020 - Parents hope funds will pay for expensive therapy not approved in Canada for type 1 spinal muscular ...
Posted by Michael Wonder on 29 Jan 2020
B.C. eye-injection program ‘clouded in secrecy’
28 January 2020 - Two dozen ophthalmologists are accusing the B.C. government of failing to properly investigate concerns that a ...
Posted by Michael Wonder on 14 Jan 2020
B.C. funding decision on pricey drug leaves teen with rare disease facing 'scary' future
13 January 2020 - Miles Ambridge just misses cut-off age to access Spinraza, a potentially life-changing treatment. ...
Posted by Michael Wonder on 04 Dec 2019
B.C. wants federal health funding lift before national pharmacare program
3 December 2019 - B.C. wants more money from Ottawa for health care before a national pharmacare program is created, ...
Posted by Michael Wonder on 10 Sep 2019
Erosion of physician and patient treatment choice continues - Alliance for Safe Biologic Medicines raises concerns for patients as British Columbia expands biologics forced switching policy
10 September 2019 - On 5 September, the Government of British Columbia announced that it would be forcibly switching 1,700 patients ...
Posted by Michael Wonder on 12 Jun 2019
New drug helps extend survival rate of men with advanced prostate cancer: B.C. Cancer Agency study
10 June 2019 - At two years, advanced prostate cancer patients taking the trial drug, in addition to their standard treatment, ...
Posted by Michael Wonder on 06 Jun 2019
Patients, physicians raise concerns with BC biosimilar non-medical switching policy
6 June 2019 - On 27 May, the Government of British Columbia announced a policy that will forcibly switch thousands ...
Posted by Michael Wonder on 28 May 2019
Canadian Biosimilars Forum applauds B.C. Government's landmark decision to enhance adoption of biosimilars and calls on remaining provinces to follow
27 May 2019 - The Canadian Biosimilars Forum today commends the Government of British Columbia for taking a decisive step ...
Posted by Michael Wonder on 28 May 2019
BC PharmaCare’s Biosimilars Initiative an important step towards improving patient access to safe and effective medicines
27 May 2019 - Biosimilars Initiative implementation could contribute to significant cost savings for the BC health care system. ...